This proof of concept study demonstrates the application of transmission Raman 12 spectroscopy (TRS) to the non-invasive and non-destructive quantification of low levels 13 (0.62 -1.32 %w/w) of an active pharmaceutical ingredient's polymorphic forms in a 14 pharmaceutical formulation. Partial least squares calibration models were validated with 15 independent validation samples resulting in prediction RMSEP values of 0.03 -0.05 % w/w 16 and a limit of detection of 0.1 -0.2 % w/w. The study further demonstrates the ability of 17 TRS to quantify all tablet constituents in one single measurement. By analysis of degraded 18 stability samples, sole transformation between polymorphic forms was observed while 19 excipient levels remained constant. Additionally, a beam enhancer device was used to 20 enhance laser coupling to the sample, which allowed comparable prediction performance at 21 60 times faster rates (0.2 s) than in standard mode.
Introduction
the ability to quantify multiple constituents of a solid dose form, [12] the ability to analyse 
87
The centre point for each component is displayed in sample no. 7. Tablets were prepared by 88 dispensing the weighed powder, total approx. 1.2g, into a pestle and mortar and grinding by 89 hand. The mixed powder was then pressed into tablets weighing approx. 110 mg (103 -115 90 mg range) and measuring approx. 2 mm (2.09 -2.18 mm range) thick. From each sample 91 10 tablets were made. 8 were used for calibration and 2 were kept aside for stability testing. working practices for PLS model building with Raman spectra.
167 validation of analytical procedures where the detection limit may be expressed as: [23] 
Conclusion

235
It has been demonstrated that transmission Raman spectroscopy has the ability to quantify Overall this work shows that transmission Raman spectroscopy as a suitable tool for 256 analysis of low level polymorphic content in final pharmaceutical forms in a rapid manner.
257
These features would make transmission Raman spectroscopy a suitable technology for at-258 line and/or real-time release and testing. 
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